Pharmacokinetics of Petrelintide in Patients with Renal Impairment for Weight Management

The primary objective of this clinical research study is to investigate how the body processes the new compound **petrelintide** in individuals with kidney problems. Understanding the pharmacokinetics of petrelintide in this population is clinically relevant as it may inform dosing adjustments and safety considerations for patients with renal impairment, who often require tailored therapeutic approaches. The study focuses on the implications for **weight management** in this specific patient group, addressing a common and significant health concern associated with kidney disease. No secondary objectives are provided in the available data.

The clinical trial focuses on **weight management** and includes a study population comprising both male and female participants. The age range of the participants falls within categories 3 and 4, which typically correspond to adults and older adults. The trial population includes individuals from vulnerable populations, although specific details regarding the selection process or the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and any specific inclusion or exclusion criteria have not been disclosed. The sponsor has not provided information on the total number of participants involved in the study.

The clinical trial is designed to evaluate the pharmacokinetics of the investigational compound **petrelintide** in individuals with kidney problems, focusing on **weight management**. This study is a Phase 3, randomized, double-blind, controlled trial, which is expected to commence recruitment on March 1, 2025, and conclude by June 1, 2026. Participants will be randomly assigned to receive either the investigational compound or a placebo, ensuring that neither the participants nor the investigators are aware of the group assignments, thus maintaining the double-blind nature of the study.

The trial will include several key visits, starting with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation of the participant's medical history, current health status, and laboratory tests to confirm eligibility. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits at specified intervals to monitor their health, assess the compound's effects, and ensure adherence to the study protocol. These visits will include physical examinations, laboratory tests, and assessments of any adverse events.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final evaluations will be conducted to gather comprehensive data on the compound's safety and efficacy. The expected duration of participant involvement is approximately 15 months, from the initial screening to the end-of-study visit. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with the study protocol, or choose to withdraw consent. The trial's design and procedures are structured to ensure the collection of robust and reliable data while prioritizing participant safety and well-being.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 1, 2025, with an estimated completion date of June 1, 2026. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials to evaluate the therapeutic benefits of the investigational product. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy outcomes.